Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody (vol 113, pg 1062, 2009)

被引：0
|
作者：
Goldenberg
机构：
来源：
BLOOD | 2009年 / 113卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：5368 / 5368
页数：1
相关论文
共 50 条
  • [11] Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder
    Ganne, V
    Siddiqi, N
    Kamaplath, B
    Chang, CC
    Cohen, EP
    Bresnahan, BA
    Hariharan, S
    CLINICAL TRANSPLANTATION, 2003, 17 (05) : 417 - 422
  • [12] Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
    Morschhauser, Franck
    Leonard, John P.
    Fayad, Luis
    Coiffier, Bertrand
    Petillon, Marie-Odile
    Coleman, Morton
    Schuster, Stephen J.
    Dyer, Martin J. S.
    Horne, Heather
    Teoh, Nick
    Wegener, William A.
    Goldenberg, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) : 3346 - 3353
  • [13] Characterization of new, chimeric and humanized, anti-CD20 monoclonal antibodies, cA20 and hA20, with equivalent efficacy to rituximab in-vitro and in xenografted human non-Hodgkin's lymphoma.
    Goldenberg, DM
    Li, XG
    Qu, ZX
    Stein, R
    Horak, ID
    Hansen, HJ
    BLOOD, 2002, 100 (11) : 575A - 576A
  • [14] PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF OCRELIZUMAB, A NOVEL, HUMANIZED ANTI-CD20 MONOCLONAL ANTIBODY IN CD20+FOLLICULAR NHL PATIENTS
    Moreira, S. A.
    Brennan, B.
    Woo, M.
    Mendila, M.
    Wassner-Fritsch, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S58 - S58
  • [15] Mechanisms of anti-lymphoma effects of a new humanized anti-CD20 monoclonal antibody, IMMU-106.
    Stein, R
    Hayes, M
    Qu, ZX
    Chen, S
    Rosario, A
    Horak, ID
    Hansen, HJ
    Goldenberg, DM
    BLOOD, 2003, 102 (11) : 298B - 298B
  • [16] Multiple signaling pathways of hexavalent anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized monoclonal antibodies correlate with improved anti-lymphoma properties
    Gupta, Pankaj
    Goldenberg, David
    Chang, Chien-Hsing
    CANCER RESEARCH, 2009, 69
  • [17] The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma
    Christian, Beth A.
    Poi, Ming
    Jones, Jeffrey A.
    Porcu, Pierluigi
    Maddocks, Kami
    Flynn, Joseph M.
    Benson, Don M.
    Phelps, Mitch A.
    Wei, Lai
    Byrd, John C.
    Wegener, William A.
    Goldenberg, David M.
    Baiocchi, Robert A.
    Blum, Kristie A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (05) : 701 - 710
  • [18] An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab (vol 14, pg 520, 2003)
    Boye, J
    Elter, T
    Engert, A
    ANNALS OF ONCOLOGY, 2003, 14 (06) : 967 - 967
  • [19] Low-Dose Humanized Anti-CD20 Monoclonal Antibody (MAb), Veltuzumab, in Adult Immune Thrombocytopenic Purpura (ITP): Initial Results of a Phase I/II Study
    Liebman, Howard A.
    Saleh, Mansoor N.
    Abassi, Rashid
    Cosgriff, Thomas M.
    Teoh, Nick
    Leoni, Matthew J.
    Wegener, William
    Goldenberg, David M.
    BLOOD, 2008, 112 (11) : 1170 - 1170
  • [20] A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
    Christian, Beth
    Alinari, Lapo
    Earl, Christian Tyler
    Wilding, Emily
    Quinion, Carl
    Lustberg, Mark
    Benson, Don M., Jr.
    Jones, Jeffrey A.
    Byrd, John C.
    Wegener, William A.
    Goldenberg, David M.
    Baiocchi, Robert A.
    Blum, Kristie A.
    BLOOD, 2010, 116 (21) : 1148 - 1149
12345